JAPAN —Japanese pharmaceutical company Shionogi has expanded its venture portfolio by investing in Celaid Therapeutics, a Tokyo-based regenerative medicine startup. The strategic investment, executed through Shionogi's corporate venture capital function, aims to advance proprietary technology focused on expanding human hematopoietic stem cells outside the body for therapeutic applications.
Celaid Therapeutics, established in October 2020 as a spinoff from research conducted at the University of Tokyo and the University of Tsukuba, develops cell therapies targeting severe hematological, genetic, and ischemic conditions. The biotechnology firm utilizes specialized techniques to selectively scale hematopoietic stem cells, which serve as the foundation for all blood cells, aiming to overcome traditional bottlenecks in clinical transplantation.
hematopoietic stem cell therapies often face critical constraints, including donor availability, insufficient cell counts for transplantation, and post-procedure complications. By supporting ex vivo stem cell expansion and gene therapy platforms, this investment addresses long-standing supply limitations in cellular medicine, potentially broadening patient access to novel clinical treatments.
For the biopharmaceutical sector, the transaction underscores growing corporate venture activity directed toward early-stage cell and gene platforms. The capital deployment aligns with broader life sciences trends where established drugmakers leverage corporate venture arms to secure early exposure to scalable manufacturing and platform innovations, bridging academic research with commercial therapeutic pipelines.
Shionogi is an Osaka-headquartered global pharmaceutical enterprise focused on researching, developing, and commercializing prescription medicines and healthcare solutions. Celaid Therapeutics is a Japanese clinical-stage startup developing advanced cell therapies and stem cell expansion platforms for rare and intractable medical conditions.
